Malignancy in dermatomyositis: A retrospective study of 201 patients seen at the University of Pennsylvania - 19/06/20
Abstract |
Background |
There is an increased incidence of malignancy in patients with dermatomyositis. It is unknown if the risk differs between the subtypes of dermatomyositis.
Objective |
To (1) compare the prevalence of malignancy-associated dermatomyositis between patients with classic and clinically amyopathic disease and (2) determine factors associated with an increased risk of malignancy-associated disease.
Methods |
Retrospective cohort study of 201 patients with adult-onset dermatomyositis prospectively enrolled in a longitudinal dermatomyositis database between July 2008 and April 2018 at an outpatient dermatology urban tertiary referral center. The main outcome measure was a diagnosis of malignancy, excluding nonmelanoma skin cancer.
Results |
There were 201 patients with adult-onset dermatomyositis: 142 (71%) classic and 59 (29%) clinically amyopathic. Within 2 years of diagnosis, the prevalences of malignancy-associated classic and clinically amyopathic dermatomyositis were 9.9% and 1.7%, respectively. In this time period, patients who were older at dermatomyositis diagnosis (P = .01) and had the classic subtype (P = .04) were significantly more likely to have an underlying malignancy on multivariable regression analysis.
Limitations |
This was a retrospective study of prospectively collected data at a single tertiary referral center.
Conclusion |
Older age and classic dermatomyositis are independent risk factors for malignancy-associated dermatomyositis within 2 years of disease onset.
Le texte complet de cet article est disponible en PDF.Key words : connective tissue disease, dermatomyositis, malignancy, medical dermatology, paraneoplastic
Abbreviations used : ANA, CADM, CDM, CI, DM, ETDM, IRB, MA, MA-CADM, MA-CDM, MA-DM, NXP-2, OR
Plan
| Funding sources: Supported by the US Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development and Biomedical Laboratory Research and Development). |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Reviewed and approved by the University of Pennsylvania IRB (approval no. 829890). |
Vol 83 - N° 1
P. 117-122 - juillet 2020 Retour au numéro
Article précédent
- Autologous cell–based therapy for male and female pattern hair loss using dermal sheath cup cells: A randomized placebo-controlled double-blinded dose-finding clinical study
- Ryoji Tsuboi, Shiro Niiyama, Ryokichi Irisawa, Kazutoshi Harada, Yosuke Nakazawa, Jiro Kishimoto
- The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata
- Nekma Meah, Dmitri Wall, Katherine York, Bevin Bhoyrul, Laita Bokhari, Daniel Asz Sigall, Wilma F. Bergfeld, Regina C. Betz, Ulrike Blume-Peytavi, Valerie Callender, Vijaya Chitreddy, Andrea Combalia, George Cotsarelis, Brittany Craiglow, Jeff Donovan, Samantha Eisman, Paul Farrant, Jack Green, Ramon Grimalt, Matthew Harries, Maria Hordinsky, Alan D. Irvine, Satoshi Itami, Victoria Jolliffe, Brett King, Won-Soo Lee, Amy McMichael, Andrew Messenger, Paradi Mirmirani, Elise Olsen, Seth J. Orlow, Bianca Maria Piraccini, Adriana Rakowska, Pascal Reygagne, Janet L. Roberts, Lidia Rudnicka, Jerry Shapiro, Pooja Sharma, Antonella Tosti, Annika Vogt, Martin Wade, Leona Yip, Abraham Zlotogorski, Rodney Sinclair
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?